RS50073B - Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama - Google Patents

Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama

Info

Publication number
RS50073B
RS50073B YUP-869/01A YUP86901A RS50073B RS 50073 B RS50073 B RS 50073B YU P86901 A YUP86901 A YU P86901A RS 50073 B RS50073 B RS 50073B
Authority
RS
Serbia
Prior art keywords
receptor
pharmacokinetic properties
vegf receptor
vegf
chimeric polypeptides
Prior art date
Application number
YUP-869/01A
Other languages
English (en)
Inventor
Nicholas J. Papadopoulos
Samuel Davis
George D. Yancopoulos
Original Assignee
Regeneron Pharmaceuticals I.N.C.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22480568&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS50073(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals I.N.C., filed Critical Regeneron Pharmaceuticals I.N.C.,
Publication of YU86901A publication Critical patent/YU86901A/sh
Publication of RS50073B publication Critical patent/RS50073B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)

Abstract

Izolovani molekul nukleinske kiseline, naznačen time, što se sastoji od: (a) nukleotidne sekvence koja kodira receptorsku komponentu vaskularnog endotelijanog faktora rasta [VEGF] koja se sastoji u osnovi od domena 2 prvog VEGF receptora sličnog imunoglobulinu (Ig) i Ig domena 3 drugog VEGF receptora; i (b) nukleotidne sekvence koja kodira multimerizacionu komponentu, gde je prvi VEGT receptor Fltl, a drugi VEGF receptor je F1kl ili Flt4 i VEGF receptorska komponenta je samo VEGF receptorska komponenta fuzionog polipeptida.
YUP-869/01A 1999-06-08 2000-05-23 Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama RS50073B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13813399P 1999-06-08 1999-06-08

Publications (2)

Publication Number Publication Date
YU86901A YU86901A (sh) 2004-05-12
RS50073B true RS50073B (sr) 2009-01-22

Family

ID=22480568

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-869/01A RS50073B (sr) 1999-06-08 2000-05-23 Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama

Country Status (33)

Country Link
EP (2) EP1544299B1 (sr)
JP (2) JP4723140B2 (sr)
KR (1) KR100659477B1 (sr)
CN (3) CN101433715B (sr)
AT (2) ATE417928T1 (sr)
AU (2) AU779303B2 (sr)
BE (1) BE2013C029I2 (sr)
BR (2) BRPI0011407B8 (sr)
CA (1) CA2376379C (sr)
CY (2) CY1108883T1 (sr)
CZ (2) CZ303656B6 (sr)
DE (2) DE60019415T2 (sr)
DK (2) DK1544299T3 (sr)
ES (2) ES2319305T3 (sr)
FR (1) FR13C0028I2 (sr)
HK (3) HK1043388A1 (sr)
HR (1) HRP20010908B1 (sr)
HU (3) HU229156B1 (sr)
IL (3) IL146890A0 (sr)
LT (1) LTC1183353I2 (sr)
LU (1) LU92195I2 (sr)
ME (2) ME00024B (sr)
MX (1) MXPA01012630A (sr)
NO (3) NO330775B1 (sr)
NZ (1) NZ515913A (sr)
PL (1) PL208247B1 (sr)
PT (2) PT1183353E (sr)
RS (1) RS50073B (sr)
RU (1) RU2265661C2 (sr)
SK (1) SK287332B6 (sr)
UA (1) UA74146C2 (sr)
WO (1) WO2000075319A1 (sr)
ZA (1) ZA200110068B (sr)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710174B2 (en) 2001-09-13 2004-03-23 Isis Pharmaceuticals, Inc. Antisense inhibition of vascular endothelial growth factor receptor-1 expression
EP1353952B1 (en) 1994-11-14 2007-04-11 Ludwig Institute For Cancer Research Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US6734017B2 (en) 2001-09-28 2004-05-11 Isis Pharmaceuticals, Inc. Antisense modulation of vascular endothelial growth factor receptor-2 expression
AU2003304173A1 (en) 2002-05-04 2005-01-04 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
CA2519787C (en) 2003-03-28 2012-06-05 Regeneron Pharmaceuticals, Inc. Methods of treating diabetes by blocking vegf-mediated activity
WO2004110360A2 (en) 2003-05-16 2004-12-23 Acorda Therapeutics, Inc. Proteoglycan degrading mutants for treatment of cns
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
EP1646353A4 (en) * 2003-05-16 2008-06-04 Acorda Therapeutics Inc FUSION PROTEINS FOR THE TREATMENT OF THE CENTRAL NERVOUS SYSTEM
EP1626989A2 (en) 2003-05-28 2006-02-22 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection by using vegf antagonists
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
CA2519875C (en) * 2003-06-06 2014-01-14 Regeneron Pharmaceuticals, Inc. Method of tumor regression with vegf inhibitors
US7399612B2 (en) 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
AR046510A1 (es) * 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
US20050112061A1 (en) * 2003-08-06 2005-05-26 Jocelyn Holash Use of a VEGF antagonist in combination with radiation therapy
JP4926962B2 (ja) 2004-05-18 2012-05-09 アコーダ セラピューティクス、インク． コンドロイチン分解酵素とその安定な製剤の精製法
JP4680997B2 (ja) * 2004-06-08 2011-05-11 ツェンドゥー カンホン バイオテクノロジーズ カンパニー リミテッド 血管新生を阻害するキメラタンパク質およびその利用
CA2567686A1 (en) * 2004-06-10 2005-12-29 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for the treatment of human cancer
AU2005265071A1 (en) * 2004-06-18 2006-01-26 Memorial Sloan-Kettering Cancer Center VEGF inhibitors for the treatment of malignant pleural effusion
CN1997386B (zh) * 2004-07-30 2012-05-30 瑞泽恩制药公司 通过阻断vegf介导的活性来治疗i型糖尿病的方法
EP1804835B9 (en) 2004-09-13 2010-09-29 Genzyme Corporation Multimeric constructs
FR2878749B1 (fr) * 2004-12-03 2007-12-21 Aventis Pharma Sa Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
US7303748B2 (en) 2005-02-02 2007-12-04 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a VEGF inhibitor
CN101141975B (zh) 2005-03-25 2012-05-23 瑞泽恩制药公司 Vegf拮抗剂制剂
ES2393748T3 (es) 2005-09-26 2012-12-27 Acorda Therapeutics, Inc. Composiciones y métodos de uso de condroitinasa ABCI mutantes
PL1962895T3 (pl) † 2005-12-16 2013-06-28 Regeneron Pharma Terapeutyczne zastosowanie antagonisty dii4 oraz inhibitora vegf do inhibicji wzrostu nowotworów
FR2895258B1 (fr) 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
CN100502945C (zh) * 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
KR101406811B1 (ko) 2006-06-16 2014-06-12 리제너론 파마슈티칼스 인코포레이티드 유리체내 투여에 적당한 ｖｅｇｆ 길항제 제형
EA018260B1 (ru) 2006-09-29 2013-06-28 Онкомед Фармасьютикалз, Инк. Антитела к дельта-подобному лиганду 4 человека и их применение
WO2008045970A2 (en) 2006-10-10 2008-04-17 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
FR2918279B1 (fr) * 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
CN101575379B (zh) * 2008-05-09 2012-05-30 上海抗体药物国家工程研究中心有限公司 可溶性vegfr双功能融合受体、其制备方法及用途
KR101698362B1 (ko) 2008-11-03 2017-01-20 몰리큘라 파트너스 아게 Ｖｅｇｆ－ａ 수용체 상호작용을 억제하는 결합 단백질
CN101838329A (zh) * 2009-03-18 2010-09-22 嘉和生物药业有限公司 抗血管新生融合蛋白
US8883145B2 (en) 2009-10-16 2014-11-11 Oncomed Pharmaceuticals, Inc. Methods of treatment with DLL4 antagonists and an anti-hypertensive agent
TWI510246B (zh) * 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
SI2601214T1 (en) 2010-08-06 2018-03-30 Genzyme Corporation VEGF antagonist compositions and their use
JP6043629B2 (ja) * 2011-01-07 2016-12-14 中外製薬株式会社 抗体の物性を改善させる方法
KR20210030510A (ko) 2011-01-13 2021-03-17 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
KR101397088B1 (ko) 2011-06-10 2014-05-19 강원대학교산학협력단 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
CA2857168C (en) * 2011-12-01 2020-10-27 Protevobio, Inc. Protein inhibitors to complement and vegf pathways and methods of use thereof
CN103304668B (zh) * 2012-03-12 2015-10-28 江苏健德生物药业有限公司 Ultra-VEGF-trap免疫融合蛋白、其制备方法及其应用
US10568934B2 (en) 2012-05-07 2020-02-25 Allergan, Inc. Method of treating AMD in patients refractory to anti-VEGF therapy
WO2014006113A1 (en) 2012-07-03 2014-01-09 Sanofi Method of treating cancer by effective amounts of aflibercept
AR093445A1 (es) 2012-11-14 2015-06-10 Regeneron Pharma Metodos para tratar el cancer de ovario con antagonistas de dll4
EP3693381A1 (en) 2013-02-18 2020-08-12 Vegenics Pty Limited Ligand binding molecules and uses thereof
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
CN104193828B (zh) * 2013-09-12 2017-04-05 北京韩美药品有限公司 同时阻断her2和vegfr信号通路的重组融合蛋白
KR20160070164A (ko) 2013-11-05 2016-06-17 알러간, 인코포레이티드 항-vegf darpin으로 눈의 병태를 치료하는 방법
EP3143044A1 (en) 2014-05-12 2017-03-22 Formycon AG Pre-filled plastic syringe containing a vegf antagonist
EP3170005B1 (en) 2014-07-18 2019-04-10 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
JP2016036322A (ja) * 2014-08-11 2016-03-22 日本化薬株式会社 血管新生因子と結合するキメラタンパク質
WO2016094673A1 (en) 2014-12-11 2016-06-16 Bayer Healthcare Llc Treatment of age related macular degeneration with a small active choroidal neovascularization lesion
GB201503453D0 (en) 2015-03-01 2015-04-15 Jain Arjun Endothelin-1"sponge"
TW202340452A (zh) 2015-08-04 2023-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
WO2017046140A1 (en) 2015-09-18 2017-03-23 Bayer Pharma Aktiengesellschaft Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
KR101936049B1 (ko) * 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
WO2017065559A1 (ko) 2015-10-15 2017-04-20 (주)알테오젠 Igg fc 도메인을 가지는 융합 단백질의 생산방법
US11654046B2 (en) 2015-11-18 2023-05-23 Sio2 Medical Products, Inc. Pharmaceutical package for ophthalmic formulations
WO2018218013A2 (en) 2017-05-24 2018-11-29 Sio2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
MX2018006092A (es) 2015-11-18 2019-01-31 Formycon Ag Envase farmacéutico precargado que comprende una formulación líquida de un antagonista del vegf.
BR112018010005A2 (pt) 2015-11-18 2018-11-21 Formycon Ag seringa pré-carregada, e, kit
WO2017084616A1 (en) * 2015-11-19 2017-05-26 Zhuhai Tairuishang Biopharm Ltd. Methods and compositions for binding vegf
HRP20231379T1 (hr) 2015-12-03 2024-02-16 Regeneron Pharmaceuticals, Inc. Postupci dovođenja u vezu genskih varijanti s kliničkim ishodom kod pacijenata koji pate od starosne makularne degeneracije liječenih anti-vegf-om
US10576128B2 (en) 2016-01-26 2020-03-03 Formycon Ag Liquid formulation of a VEGF antagonist
US20190300607A1 (en) 2016-10-12 2019-10-03 Daiichi Sankyo Company, Limited Composition containing anti-robo4 antibody and other agents
CN109937034B (zh) 2016-11-21 2022-09-16 济世-伊沃泰克生物制品有限公司 阿柏西普制剂及其用途
WO2018217995A1 (en) 2017-05-24 2018-11-29 Formycon Ag Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
WO2018215580A1 (en) 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
EP3668985B1 (en) 2017-08-17 2021-06-16 Just-Evotec Biologics, Inc. Method of purifying glycosylated protein from host cell galectins and other contaminants
CN111356471A (zh) 2017-11-20 2020-06-30 济世发展生物药业有限公司 包含赖氨酸盐作为张力调节剂的阿柏西普制剂及其用途
CN111770999A (zh) 2017-11-27 2020-10-13 4D分子治疗有限公司 腺相关病毒变体衣壳和用于抑制血管生成的应用
IL274711B1 (en) 2017-11-30 2024-06-01 Regeneron Pharma Use of VEGF antagonist to treat angiogenic eye disorders
AU2018385394B2 (en) * 2017-12-13 2024-05-02 Regeneron Pharmaceuticals, Inc. Devices and systems for chromatography column bed support management and related methods
WO2019147944A1 (en) * 2018-01-26 2019-08-01 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disordres using anti-vegf agents
EP4364724A2 (en) 2018-05-10 2024-05-08 Regeneron Pharmaceuticals, Inc. High concentration vegf receptor fusion protein containing formulations
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
CN111378044B (zh) 2018-12-28 2022-07-15 长春金赛药业有限责任公司 抗体融合蛋白、制备方法及其应用
EP3969564A1 (en) 2019-05-16 2022-03-23 Formycon AG Method for reducing methionine oxidation in recombinant proteins
WO2021046070A1 (en) 2019-09-03 2021-03-11 Amgen Inc. Injection device for drug delivery and packaging for the injection device
US20210077645A1 (en) 2019-09-16 2021-03-18 Amgen Inc. Method for external sterilization of drug delivery device
JP2022553640A (ja) 2019-10-10 2022-12-26 コディアック サイエンシーズ インコーポレイテッド 眼障害を処置する方法
CN114867487A (zh) 2019-11-25 2022-08-05 加利福尼亚大学董事会 用于眼内新生血管的长效vegf抑制剂
BR112022010686A2 (pt) 2019-12-06 2022-08-23 Regeneron Pharma Mini-traps de vegf e métodos de uso dos mesmos
IL302538A (en) * 2019-12-06 2023-07-01 Regeneron Pharma Anti-VEGF protein preparations and methods for their production
US20210261297A1 (en) 2020-02-24 2021-08-26 Amgen, Inc. Containers and systems for use during external sterilization of drug delivery devices
EP4145456A1 (en) 2021-09-06 2023-03-08 Bayer AG Prediction of a change related to a macular fluid
WO2023092324A1 (zh) 2021-11-24 2023-06-01 苏州光度生物科技有限公司 多特异性配体结合分子及其应用
KR20240019034A (ko) * 2022-08-02 2024-02-14 주식회사 파노로스바이오사이언스 변형된 융합 단백질 및 이의 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production

Also Published As

Publication number Publication date
NO332559B1 (no) 2012-10-29
LTC1183353I2 (lt) 2023-02-27
ES2237429T3 (es) 2005-08-01
HU230159B1 (hu) 2015-09-28
NO330775B1 (no) 2011-07-11
NO2013010I1 (no) 2013-06-17
HU229156B1 (en) 2013-09-30
HK1185798A1 (en) 2014-02-28
SK287332B6 (sk) 2010-07-07
PL208247B1 (pl) 2011-04-29
HUS1300052I1 (hu) 2016-08-29
PT1544299E (pt) 2009-03-18
EP1544299A1 (en) 2005-06-22
DK1544299T3 (da) 2009-03-23
BR0011407A (pt) 2002-04-02
AU779303B2 (en) 2005-01-13
CZ302689B6 (cs) 2011-09-07
YU86901A (sh) 2004-05-12
AU5040400A (en) 2000-12-28
DK1183353T3 (da) 2005-08-08
HUP0201515A2 (en) 2002-08-28
PT1183353E (pt) 2005-06-30
CY1108883T1 (el) 2014-07-02
DE60019415T2 (de) 2006-03-09
JP5273746B2 (ja) 2013-08-28
HRP20010908B1 (en) 2006-05-31
PL352246A1 (en) 2003-08-11
CN101433715B (zh) 2013-04-17
CN1369009A (zh) 2002-09-11
EP1544299B1 (en) 2008-12-17
BE2013C029I2 (sr) 2019-03-06
ATE293164T1 (de) 2005-04-15
FR13C0028I2 (fr) 2014-05-16
CA2376379A1 (en) 2000-12-14
CY2013019I2 (el) 2015-11-04
DE60041159D1 (de) 2009-01-29
ME00024B (me) 2010-02-10
LTPA2013009I1 (lt) 2013-06-25
AU2005201365B2 (en) 2007-08-09
BRPI0011407B1 (pt) 2018-09-25
ES2319305T3 (es) 2009-05-06
UA74146C2 (uk) 2005-11-15
NZ515913A (en) 2004-01-30
EP1183353B1 (en) 2005-04-13
IL146890A0 (en) 2002-08-14
WO2000075319A1 (en) 2000-12-14
NO20100656L (no) 2002-02-08
JP2011024595A (ja) 2011-02-10
SK17522001A3 (sk) 2003-04-01
DE60019415D1 (de) 2005-05-19
MEP3208A (xx) 2010-02-10
KR20020019070A (ko) 2002-03-09
CY2013019I1 (el) 2015-11-04
CZ20014387A3 (cs) 2002-10-16
CN103349781A (zh) 2013-10-16
CN100523187C (zh) 2009-08-05
AU2005201365A1 (en) 2005-04-28
BRPI0011407B8 (pt) 2021-05-25
NO20016036D0 (no) 2001-12-10
RU2265661C2 (ru) 2005-12-10
FR13C0028I1 (fr) 2013-06-14
IL146890A (en) 2008-07-08
MXPA01012630A (es) 2002-07-22
KR100659477B1 (ko) 2006-12-20
CN101433715A (zh) 2009-05-20
NO2013010I2 (no) 2013-05-15
HK1043388A1 (en) 2002-09-13
CA2376379C (en) 2007-08-07
LU92195I2 (fr) 2013-07-15
HK1132653A1 (en) 2010-03-05
CN103349781B (zh) 2015-04-01
NO20016036L (no) 2002-02-08
JP4723140B2 (ja) 2011-07-13
HUP0201515A3 (en) 2004-12-28
HRP20010908A2 (en) 2005-04-30
JP2003501089A (ja) 2003-01-14
ATE417928T1 (de) 2009-01-15
CZ303656B6 (cs) 2013-01-30
ZA200110068B (en) 2002-12-06
IL190234A0 (en) 2008-11-03
EP1183353A1 (en) 2002-03-06

Similar Documents

Publication Publication Date Title
RS50073B (sr) Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama
AU4260897A (en) Cxcr3 chemokine receptor, antibodies, nucleic acids, and methods of use
UA105625C2 (uk) Пастка vegf і її терапевтичне застосування
WO2000037502A3 (en) Vascular endothelial cell growth factor antagonists and uses thereof
WO2000018932A3 (en) Receptor based antagonists and methods of making and using
EE9800373A (et) Moraxella catarrhalis välismembraani proteiin-106 polüpeptiid, geenijärjestus ja selle kasutamine
DE60033402D1 (de) In-vitro-selektion and wahlweiser nachweis von polypeptiden unter verwendung von festphasenträgern
AU1846995A (en) Heterologous g protein coupled receptors expressed in yeast, their fusion with g proteins and use thereof in bioassay
DK0619839T3 (da) Nye polypeptider til fremme af cellebinding
DK0888384T3 (da) Fusionspolypeptid til påvirkning af vekselvirkninger mellem proteiner
WO2003060143A3 (en) Efficient protein expression system
DE69634077D1 (de) Haemophilus adhäsionsproteinen
CA2240409A1 (en) Mammalian cx3c chemokine genes
WO1998032858A3 (en) Mammalian chemokines; receptors; reagents; uses
DK0635025T3 (da) Fremgangsmåde til fremstilling af modificerede proteiner
EP0384163A3 (de) Polyetheramid-Schmelzklebstoffe
WO1998020343A3 (de) Rezeptorbindungsassay, für den rezeptorbindungsassay geeigneter rekombinanter fusionsrezeptor, vektor zu dessen herstellung sowie reagenziensatz für die durchführung des rezeptorbindungsassays
WO1998031810A3 (en) Mammalian chemokines; receptors; reagents; uses
AU1444699A (en) Single-chain polypeptides comprising troponin i and troponin
DE69333803D1 (de) Polypeptide mit opioider rezeptor-aktvität, für sie kodierende nukleinsäuren und ihre verwendungen
KR950000874A (ko) 미생물에서의 시그날 형질도입을 사용한, 리간드 결합가능 단백질의 유전적 선별방법
DE69939694D1 (de) 'patched-2' protein aus wirbeltieren
WO2004005335A3 (en) Multimerised growth hormone fusion proteins
DK1078072T3 (da) Nye peptidfragmenter til oprensning af proteiner
SE0003573D0 (sv) Method and means for producing novel von Willebrand factor binding proteins and their use in biotechnology